Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aletaha Daniel, Kerschbaumer Andreas, Kastrati Kastriot, Dejaco Christian, Dougados Maxime, McInnes Iain B, Sattar Naveed, Stamm Tanja A, Takeuchi Tsutomu, Trauner Michael, van der Heijde Désirée, Voshaar Marieke, Winthrop Kevin L, Ravelli Angelo, Betteridge Neil, Burmester Gerd-Rüdiger R, Bijlsma Johannes Wj, Bykerk Vivian, Caporali Roberto, Choy Ernest H, Codreanu Catalin, Combe Bernard, Crow Mary K, de Wit Maarten, Emery Paul, Fleischmann Roy M, Gabay Cem, Hetland Merete Lund, Hyrich Kimme L, Iagnocco Annamaria, Isaacs John D, Kremer Joel M, Mariette Xavier, Merkel Peter A, Mysler Eduardo F, Nash Peter, Nurmohamed Michael T, Pavelka Karel, Poor Gyula, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Strangfeld Anja, Tanaka Yoshiya, Smolen Josef S
Аннотация
METHODS: A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document.
RESULTS: The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring.
CONCLUSIONS: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.